Albemarle Operating Cash Flow decreased by 10.9% to $346.24M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 36.7%, from $547.21M to $346.24M. Over 3 years (FY 2022 to FY 2025), Operating Cash Flow shows a downward trend with a -14.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $227.90M | $104.73M | $206.18M | $0.00 | $895.29M | $956.81M | $720.98M | $73.71M | $628.85M | $0.00 | $97.49M | $367.66M | $227.11M | $0.00 | $547.21M | $0.00 | $355.60M | $388.49M | $346.24M |
| QoQ Change | — | -54.0% | +96.9% | -100.0% | — | +6.9% | -24.6% | -89.8% | +753.2% | -100.0% | — | +277.1% | -38.2% | -100.0% | — | -100.0% | — | +9.2% | -10.9% |
| YoY Change | — | — | — | -100.0% | +754.8% | — | +249.7% | — | -29.8% | -100.0% | -86.5% | +398.8% | -63.9% | — | +461.3% | -100.0% | +56.6% | — | -36.7% |